Continuous hyperfractionated accelerated radiotherapy (CHART) in localized cancer of the esophagus

被引:25
作者
Powell, MEB [1 ]
Hoskin, PJ [1 ]
Saunders, MI [1 ]
Foy, CJW [1 ]
Dische, S [1 ]
机构
[1] MT VERNON HOSP,NORTHWOOD HA6 2RN,MIDDX,ENGLAND
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1997年 / 38卷 / 01期
关键词
CHART; accelerated hyperfractionation; esophageal cancer;
D O I
10.1016/S0360-3016(96)00582-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess the efficacy and toxicity of continuous hyperfractionated accelerated radiotherapy( CHART) in locoregional control compared with a historical group of patients treated with conventionally fractionated radical radiotherapy. Methods and Materials: Between 1985 and 1994, 54 patients with localized esophageal cancer were treated with CHART, Twenty-eight patients received CHART alone (54 Gy in 36 fractions over 12 consecutive days) and 15 were given intravenous mitomycin C and cisplatin on days 10 and 13, respectively. Eleven patients received 40.5 Gy in 27 fractions over 9 days, followed by a single high-dose-rate intraluminal brachytherapy insertion of 15 Gy at 1 cm. Results: Acute toxicity was well tolerated and dysphagia was improved in 35 patients (65%), with 28 (52%) eating a normal diet by week 12, This compares with an improvement in dysphagia score in 72% of the conventionally treated group, The median duration of relief of dysphagia was 7.8 months (range 0-41.4) in the CHART group compared with 5.5 months (range 0-48) in the controls, Strictures developed in 29 patients (61%) and 18 were confirmed on biopsy to be due to recurrent disease, Median survival was 12 months (range 0.5-112) in the CHART group and 15 months (range 3.6-56) in the control patients. Conclusion: CHART is well tolerated and achieves a high rate of local control, Palliation in the short overall treatment time of esophageal cancer is an advantage in these patients whose median survival is only 12 months. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:133 / 136
页数:4
相关论文
共 13 条
[1]   THERAPY OF CARCINOMA OF THE ESOPHAGUS - EITHER ATTEMPT IT NOT OR SUCCEED [J].
AJANI, JA .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (05) :790-793
[2]  
ALBERTSSON M, 1989, ACTA ONCOL, V28, P8
[3]  
BEATTY JD, 1979, CANCER-AM CANCER SOC, V43, P2254, DOI 10.1002/1097-0142(197906)43:6<2254::AID-CNCR2820430616>3.0.CO
[4]  
2-A
[5]  
DEPAOLI A, 1988, INT J RADIAT ONCOL, V19, P61
[6]   THE RECORDING OF MORBIDITY RELATED TO RADIOTHERAPY [J].
DISCHE, S ;
WARBURTON, MF ;
JONES, D ;
LARTIGAU, E .
RADIOTHERAPY AND ONCOLOGY, 1989, 16 (02) :103-108
[7]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[8]  
Laing J H, 1992, BJR Suppl, V24, P163
[9]  
Leslie M D, 1992, Clin Oncol (R Coll Radiol), V4, P114, DOI 10.1016/S0936-6555(05)80981-1
[10]   ESOPHAGEAL CANCER TREATED WITH RADIOTHERAPY - IMPACT OF TOTAL TREATMENT TIME AND FRACTIONATION [J].
NISHIMURA, Y ;
ONO, K ;
TSUTSUI, K ;
OYA, N ;
OKAJIMA, K ;
HIRAOKA, M ;
ABE, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 30 (05) :1099-1105